Display options
Cite
Hoegy D, Martin J, Barral M, et al. Development of clinical pharmacy programs integrated into patient care pathways using adverse event risks. Res Social Adm Pharm. 2021;doi: 10.1016/j.sapharm.2021.08.005.
Hoegy, D., Martin, J., Barral, M., Ranchon, F., Janoly-Dumenil, A., Delande, E., Pivot, C., Mouchoux, C. (2021). Development of clinical pharmacy programs integrated into patient care pathways using adverse event risks. Research in social & administrative pharmacy : RSAP, . https://doi.org/10.1016/j.sapharm.2021.08.005
Hoegy, Delphine, et al. "Development of clinical pharmacy programs integrated into patient care pathways using adverse event risks." Research in social & administrative pharmacy : RSAP vol. (2021). doi: https://doi.org/10.1016/j.sapharm.2021.08.005
Hoegy D, Martin J, Barral M, Ranchon F, Janoly-Dumenil A, Delande E, Pivot C, Mouchoux C. Development of clinical pharmacy programs integrated into patient care pathways using adverse event risks. Res Social Adm Pharm. 2021 Aug 08; doi: 10.1016/j.sapharm.2021.08.005. Epub 2021 Aug 08. PMID: 34389258.
Copy Download .nbib Format: NLM
Share it on

Res Social Adm Pharm. 2021 Aug 08; doi: 10.1016/j.sapharm.2021.08.005. Epub 2021 Aug 08.

Development of clinical pharmacy programs integrated into patient care pathways using adverse event risks.

Research in social & administrative pharmacy : RSAP

Delphine Hoegy, Julie Martin, Marine Barral, Florence Ranchon, Audrey Janoly-Dumenil, Evariste Delande, Christine Pivot, Christelle Mouchoux,

Affiliations

  1. EA 4129 P2S Parcours Santé Systémique- Univ Claude Bernard Lyon 1, Univ Lyon 1, Lyon, France; Pharmacie, Hospices Civils de Lyon, Lyon, France; Institut des Sciences Pharmaceutiques et Biologiques, Univ Claude Bernard Lyon 1, Univ Lyon 1, Lyon, France. Electronic address: [email protected].
  2. Pharmacie, Hospices Civils de Lyon, Lyon, France.
  3. Institut des Sciences Pharmaceutiques et Biologiques, Univ Claude Bernard Lyon 1, Univ Lyon 1, Lyon, France; Pharmacie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; EMR3738, Université de Lyon, Lyon, France.
  4. EA 4129 P2S Parcours Santé Systémique- Univ Claude Bernard Lyon 1, Univ Lyon 1, Lyon, France; Institut des Sciences Pharmaceutiques et Biologiques, Univ Claude Bernard Lyon 1, Univ Lyon 1, Lyon, France; Pharmacie Groupement Hospitalier Centre, Hospices Civils de Lyon, Lyon, France.
  5. Pharmacie Renée Sabran, Hospices Civils de Lyon, Lyon, France.
  6. Pharmacie Groupement Hospitalier Centre, Hospices Civils de Lyon, Lyon, France.
  7. Institut des Sciences Pharmaceutiques et Biologiques, Univ Claude Bernard Lyon 1, Univ Lyon 1, Lyon, France; Pharmacie Groupement Hospitalier Centre, Hospices Civils de Lyon, Lyon, France; Inserm U1028, CNRS UMR5292, Centre de recherche en neurosciences de Lyon, Bron, France.

PMID: 34389258 DOI: 10.1016/j.sapharm.2021.08.005

Abstract

BACKGROUND: In the strained actual economic context, all clinical pharmacy activities cannot be achieved for all patients of all care pathways. So finding a way to prioritize moments and patients needing those activities is essential. This is the challenge of the "5P project" (Patient personalized clinical pharmacy program integrated into care pathway).

OBJECTIVE: To present adverse event (AE) risk management approach applied to develop clinical pharmacy programs integrated into care pathway, using two methods.

METHOD: Used as a priori AE risk management approach, the Delphi method and inductive approach analysis of semi-directed interviews were realized from April 1st to October 3rd

RESULTS: The Delphi method for OG care pathway has revealed: 1/. Patients were prioritized by the presence of at least 2 among the following 4 criteria: age ≥90 years old, cardiovascular diseases, prescribed potentially inappropriate medication for elderly patients, obesity or diabetes; priority steps were the post-operative and rehabilitation care steps. 2/. Prescription reviews, medication reconciliation and targeted pharmaceutical informative interview about oral anticoagulants were required. Nine semi-directed interviews used for PKT care pathway has revealed: 1/. Clinical pharmacy activities were carried out for all patients. Priority steps were pre-transplantation, immediate post-operative, and post-transplantation. 2/. Prescription reviews and educative interviews were required.

CONCLUSIONS: The two presented methods can be used to both develop patient prioritization and targeting steps for clinical pharmacy activities, and integrate it into care pathway. Today, those two developed programs have been executed in our teaching hospital.

Copyright © 2021. Published by Elsevier Inc.

Keywords: Care pathway; Clinical pharmacy; Qualitative research; Risk management

Publication Types